Provider Communication

Pharmacists Are Excluded in Burnout Conversations

November 30, 2022 - Throughout the COVID-19 pandemic, many experts, industry leaders, and public health officials discussed workplace burnout and its effects on the healthcare industry. The discussion centered on physicians and nurses who saw unprecedented workloads and stress levels. Unfortunately, the conversation failed to include one key player: pharmacists. Physician and nurse burnout is well...

Read More


More Articles

How Can Providers Help Patients Navigate Increased Drug Costs?

by Veronica Salib

In a recent press release, GoodRx, a digital healthcare platform, launched Provider Mode. Provider Mode is a new experience that is specifically targeted to healthcare professionals (HCPs). PharmaNewsIntelligence interviewed Preeti Parikh,...

How to Integrate Remote Patient Monitoring Across Cancer Care Settings

by Veronica Salib

In recent years, remote patient monitoring tools have gained traction as they have been introduced and integrated into patient care. The uptick in the use of remote patient monitoring tools and platforms was driven, in part, by travel...

Patients, Providers, and the Public Hesitate to Adopt Digital Pills

by Veronica Salib

On November 13, 2017, Abilify MyCite became the first digital pill approved by the United States FDA. Since this approval and the initial surge of digital pills — sometimes called smart pills — the uptake and utilization have...

Pharmacists’ Role to Expand to Direct Patient Care by 2030

by Samantha McGrail

Despite growing provider shortages, pharmacists in the US are well-trusted by patients and projected to play an increasingly crucial role in healthcare management, according to research from Columbia...

Cerner Invests in Elligo to Boost Access to Clinical Trials

by Samantha McGrail

Cerner recently announced that an investment in Elligo Health Research will increase access to clinical trials by offering clinical trial resourcesin the Cerner Learning Health...

FDA Seeks to Clarify Evidence for Intended Use Determinations

by Samantha McGrail

FDA recently proposed updates to its regulations to clarify the types of evidence the agency considers when determining the “intended use” of FDA-regulated products.  The proposed...

Pharma Sales Reps Must Understand Provider Needs During COVID-19

by Samantha McGrail

Although 61 percent of healthcare providers communicate with pharmaceutical sales representatives now more than before COVID-19, they stressed that sales reps fail to understand the real impact of the...

Phase 3 Trial Finds Positive Results for Microbiome Treatment

by Samantha McGrail

Rebiotix and Ferring Pharmaceuticals recently announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome therapy treatment, RBX2660. The...

Recent Articles